Japanese Journal of Cancer and Chemotherapy最新文献

{"title":"[A Case of Descending Colon Cancer Resulting in Cecal Perforation and Necrosis of the Large Intestine Due to Obstructive Colitis].","authors":"Ryoji Kamei, Taro Hamasaki, Hiroki Umeno, Hiroki Nakatsu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An 81-year-old woman had been constipated for a week and experienced nausea and decreased appetite 3 days earlier. She developed chills and general fatigue and was referred to our department. A plain abdominal computed tomography (CT)scan showed wall thickening of the descending colon, the oral side of the intestine was significantly dilated and filled with fecal masses, the anal side of the intestine was collapsed, and ascites and free air were present. Emergency surgery was performed. The area from the cecum to the descending colon was markedly dilated, and a tumor was identified in the descending colon. Fecal fluid leaked from 2 locations on the anterior wall of the cecum, and the walls from the cecum to the ascending colon were poorly colored and necrotic. The necrotic intestine was resected, and an ileostomy and transverse colon mucous fistula were constructed. Radical surgery was performed 26 days after the surgery. Invasion of the transverse colon by descending colon cancer was suspected; therefore, we performed resection from the transverse colon to the sigmoid colon, D3 dissection, and transverse colon-sigmoid colon anastomosis. After adjuvant chemotherapy, the ileostomy and mucous fistula were closed. Nearly 3 years have passed since the radical surgery, and the patient is currently under follow-up with no recurrence.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"246-248"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Long-Term Prognosis of Advanced Rectosigmoid Cancer with Multiple Metastases Treated with Multidisciplinary Therapy].","authors":"Yasutaka Shimada, Tetsuro Ikeya, Masato Satake, Kuniyasu Murahashi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The case was 50-year-old woman, who was diagnosed with advanced rectosigmoid cancer with multiple liver metastases and solitary lung metastasis. She was started with chemotherapy. Two courses of mFOLFOX6+panitumumab and 8 courses of mFOLFOX6+bevacizumab were administered as a first-line. As a second-line, 1 course of FOLFIRI+ramucirumab was given. Six months later, CT showed that lung metastasis had disappeared and all liver metastases had become smaller, therefor surgery was selected. Laparoscopic partial hepatectomy was performed, and 2 months later, laparoscopic high anterior resection was added. She received 4 courses of capecitabine as adjuvant chemotherapy, but the lung metastasis had enlarged, and thoracoscopic partial lung resection was performed. Five months later, a nodule suspected metastasis was noted on the dissected surface of liver S5 on CT, and a right liver lobectomy was added. She was surviving for 2 years and 10 months after diagnosis of Stage Ⅳ rectal cancer, and had been progression-free for 10 months after last treatment.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"243-245"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histologic Types of Peritoneal Disease in Pseudomyxoma Peritonei as Prognostic Factor.","authors":"Yutaka Yonemura, Haruaki Ishibashi, Akiyoshi Mizumoto, Takuji Fujita, Yang Liu, Satoshi Wakama, Sachio Fushida, Shouzou Sako, Nobuyuki Takao, Toshiyuki Kitai, Yasuo Hirono, Keizou Taniguchi, Daisuke Fujimoto, Rei Noguchi, Shizuki Takemura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The present study aims the prognostic significance of the histologic classification of peritoneal disease of pseudomyxoma peritonei(PMP)from appendix.</p><p><strong>Patients: </strong>During the last 15 years, 1,117 patients were histologically diagnosed for primary and peritoneal disease components according to the new WHO classification by Carr. Primary appendiceal tumors are classified into low grade appendiceal mucinous neoplasm(LAMN), high grade appendiceal mucinous neoplasm(HAMN), and mucinous neoplasm with signet ring cell carcinoma(Sig). The histologic types of peritoneal disease components were classified into four groups, ie, acellular mucin(AM), mucinous carcinoma peritonei with low grade histologic feature(LGMCP), that with high grade histologic type(HGMCP), high grade mucinous carcinoma peritonei with signet ring cells(HGMCP-S).</p><p><strong>Results: </strong>Among 1,117 primary tumors, 834(74.7%), 221(19.8%), and 62(5.5%)shows LAMN, HAMN and Sig, respectively. Histologic types of peritoneal disease from LAMN changed to AM, HGMCP, and HGMCP-S. were found in 251 (30.1%), 173(20.7%), and 19(2.3%), respectively. Among 221 patients with HAMN, histologic type of peritoneal disease changed to AM, LGMCP, and HGMCP-S in 12(5.4%), 15(6.8%)and 35(15.8%), respectively, Among 62 patients whose primary tumors were Sig, 4(6.5%), 5(8.1%), and 5(8.1%)showed AM, LGMCP, and HGMCP, respectively. Patients with AM shows the best survival curves with 10 year-survival rate of 86.9%. The 10-year survival rates of LGMCP, HGMCP, and HGMCP-S were 63.7%, 32.2%, and 10.1%, respectively(p=0.00023). In patients with primary tumor showing LAMN, the 10-year survival rates of AM, LGMCP, HGMCP, and HGMCP-S of peritoneal disease were 91.9%, 73.2%, 49.6%, and 23.9%, respectively(p<0.0001). In patients with primary tumor showing HAMN without signet ring cell component, the 10-year survival rates of AM or LGMCP and HGMCP or HGMCP-S were 58.6%, and 21.6%, respectively(p<0.001). In patients with primary tumor having signet ring cell component, 10-year survival rates of AM or LGMCP and HGMCP or HGMCP-S were 61.3% and 19.4%, respectively.</p><p><strong>Conclusions: </strong>Postoperative survival of patients with PMP significantly correlates with pathologic features of peritoneal disease. Accordingly, CRS should be performed after the intraoperative pathologic diagnosis of peritoneal disease.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"275-278"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Advanced Breast Cancer with Axillary Lymph Node Metastasis Complicated by Neurofibromatosis Type 1].","authors":"Chihiro Kawata, Hirofumi Terakawa, Yuki Kurokawa, Yuka Ohe, Ryosuke Mohri, Miki Hirata, Tomomi Kitahara, Hideki Moriyama, Jun Kinoshita, Hiroko Kawashima, Noriyuki Inaki","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient was a 55-year-old woman who had been diagnosed with neurofibromatosis type 1(NF1)since she was young. A 50 mm mass with skin changes was palpated on the outside of the left breast. As a result of a detailed examination of the whole body, invasive ductal carcinoma of Luminal B like was observed, and cT4N1M0, Stage ⅢB left breast cancer was diagnosed. After preoperative chemotherapy, total left mastectomy and axillary lymph node dissection were performed. NF1 is an autosomal overt inherited disease characterized by multiple neurofibromas and pigment spots. It is called von Recklinghausen disease, and it is said that there are many complications of malignant tumors such as breast cancer, mainly nervous system tumors. In breast cancer complicated by NF1, there is a high rate of diagnosis as advanced cancer due to delayed awareness of breast masses due to unique skin lesions and a tendency to refrain from visiting medical institutions or medical examinations due to latent shame about appearance. In this study, we report 1 case of advanced breast cancer complicated by NF1.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"255-257"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Stage Ⅳ Gastric Cancer with Distant Metastasis That Underwent Curative Surgery and Achieved Complete Response in Primary Lesion after Systemic Chemotherapy with Nivolumab].","authors":"Junichi Fujii, Keijirou Sugimura, Toru Masuzawa, Yoshirou Yukawa, Shinsuke Katsuyama, Asami Arita, Kiminori Yanagisawa, Go Shinke, Mitsuru Kinoshita, Masayuki Hiraki, Yoshifumi Iwagami, Yoshiaki Ohmura, Taishi Hata, Yutaka Takeda, Kouhei Murata","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We report a case of Stage Ⅳ gastric cancer, in case systemic chemotherapy with nivolumab was effective and curative resection was possible. A man in his 50s visited our hospital with complaints of general fatigue and anemia. Esophagogastroduodenoscopy revealed a type 3 tumor extending from the gastric cardia to angler incisure in the stomach. Abdominal contrast-enhanced computed tomography showed pancreatic invasion from the primary tumor and multiple lymph node metastases. Additionally, a single subcutaneous nodule around the umbilicus was detected. Staging laparoscopy showed P0, CY0. Excisional biopsy of subcutaneous nodule confirmed adenocarcinoma, diagnosing it as skin metastasis. The patient was diagnosed as advanced gastric cancer cT4bN3P0CY0M1(skin), cStage Ⅳ. Five courses of SOX with nivolumab therapy were administered. After 4 months, examinations showed clinical response in the primary lesion and lymph nodes. No new distant metastases were observed, and curative surgery was considered possible. Laparoscopic total gastrectomy with D2 lymphadenectomy, combined resection of distal pancreatectomy and spleen, Roux-en-Y reconstruction, was performed. Pathological examination revealed no residual cancer, indicating a histopathological evaluation of Grade 3. No complications were observed postoperatively and the patient was discharged on the 19th postoperative day. No recurrence was observed 6 months post-surgery. The administration of chemotherapy combined with immune checkpoint inhibitors for oligometastatic Stage Ⅳ gastric cancer was effective and resulted in curative surgery.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"279-281"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Decentralized Clinical Trials in Cancer Patients].","authors":"Tetsuya Sasaki, Kenichi Nakamura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Clinical trials are conducted at a limited number of medical institutions, and patients living in areas far from these sites sometimes give up participating in clinical trials due to the time, financial, and physical burdens associated with hospital visits, even if they wish to do so. A survey conducted by the National Cancer Center Hospital has revealed that participation rates in clinical trials tend to decrease when travel time exceeds 120 minutes one way. Additionally, among patients who underwent cancer panel testing under the national health insurance, only 9.4% received the treatments recommended by the expert panel, partly due to the inability of patients living far away to travel to urban medical institutions. The decentralized clinical trials(DCTs)discussed in this paper are one potential solution to these issues. This article will cover the latest regulatory requirements for DCTs, the different types of DCTs, and the necessary preparations for medical institutions and partner sites, based on a case from the National Cancer Center Hospital. It will also address topics such as eConsent, telemedicine, sharing of trial data, the delivery of investigational medicinal products, and medical expenses associated with DCTs.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"191-197"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case Report of Ascending Colon Cancer with Intestinal Tuberculosis].","authors":"Tomoya Tokuno, Manabu Kurayoshi, Masahiro Nakahara, Tetsushi Nakagawa, Mai Nishina, Kousuke Ono, Hiroyuki Otsuka, Daisuke Takei, Senichiro Yanagawa, Yuji Yamamoto, Minoru Yamaki, Junji Hashizume, Akihiko Oshita, Toshio Noriyuki","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 67-year-old man tested positive for fecal occult blood during a medical checkup. Colonoscopy revealed 2 circular narrowing sections and ulcers in the ascending colon. Subsequently, intestinal tuberculosis was suspected, and a biopsy revealed a well-differentiated adenocarcinoma. The patient underwent laparoscopic right colectomy. Pathological findings revealed adenocarcinoma, caseous granuloma, and acid-fast bacteria in the lesions. Therefore, we report a case of ascending colon cancer with intestinal tuberculosis.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"269-271"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Advanced Gastric Cancer in Which Complete Pathological Response to Pre-Operative SOX and Nivolumab Therapy Was Noted Despite Severe Liver Dysfunction].","authors":"Naoko Yoneura, Eisuke Kondo, Kei Nishiya, Katsuhiko Ito, Koya Yokoyama, Kimio Shimizu, Yasuhide Onai, Yasuyuki Nakata, Ayako Nakagawa, Kenji Kawahara, Yoshiaki Shimizu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 63-year-old man with anemia was diagnosed as having cStage ⅣB gastric cancer with liver metastases. The patient was treated with SOX and nivolumab. After 3 courses of treatment, nivolumab administration was discontinued because of thyroiditis, and SOX was administered for 2 courses. Treatment resulted in RECIST: PR and surgery was planned. An indocyanine green(ICG)clearance test and 99mTc-GSA liver scintigraphy showed poor liver function, and liver biopsy revealed nivolumab-related hepatitis. After the recovery of liver function, the patient underwent total gastrectomy with splenectomy. However, he developed prolonged ascites postoperatively. Hepatitis/hepatotoxicity has been reported as an immune-related adverse event associated with nivolumab administration; however, its effect on surgery remains unknown.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"240-242"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Perforation of Small Intestinal Gastrointestinal Stromal Tumor Required Emergency Surgery-A Case Report].","authors":"Masanori Ikota, Taku Akahoshi, Ippei Murata, Rama Adikrisna, Tomoyuki Ohta, Kenjiro Kitasato, Sho Mineta, Yoshihiko Tsuruta","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The case was a 77-year-old man. He presented with abdominal pain and melena to our hospital. Abdominal CT showed thickening of the small intestinal wall and findings of intraperitoneal free air. Suspecting peritonitis due to small intestinal tumor perforation, we performed an emergency surgery. A ruptured tumor measuring 50 mm in diameter was found in the jejunum about 15 cm from the Treitz' ligament and the partial resection of the small intestine was performed. Histopathology revealed fistulous necrosis within the tumor, and immunostaining was positive for KIT and CD34, leading to the diagnosis of jejunal GIST. He was evaluated as high risk for recurrence and was indicated for adjuvant chemotherapy. He is currently taking imatinib and is being followed up for 6 months without recurrence. Although diagnosing GIST of small intestine can be difficult, GIST of small intestine with perforation is at high risk of recurrence and rezuires adjuvant chemotherapy. Emergency surgical diagnosis should not be hesitated.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 2","pages":"182-184"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Unresectable Hepatocellular Carcinoma Treated with Conversion Surgery after Preoperative Atezolizumab and Bevacizumab Therapy].","authors":"Kenta Fukuda, Junzo Shimizu, Katsunori Matsushita, Masafumi Yamashita, Toshiki Noma, Kiyotaka Hagihara, Yoshitomo Yanagimoto, Yozo Suzuki, Masakazu Ikenaga, Tomono Kawase, Naohiro Tomita, Hiroshi Imamura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 1-year survival rate of patients with unresectable hepatocellular carcinoma is less than 50%, which indicates a poor prognosis. Recently, the combination of atezolizumab and bevacizumab has improved the prognosis of patients with advanced hepatocellular carcinoma and has become the first-line treatment for unresectable hepatocellular carcinoma. However, there are few reports on conversion surgery after chemotherapy for unresectable hepatocellular carcinoma. Here, we report the case of a 92-year-old man with no significant complaints. During follow-up, the tumor was found to be enlarged, and abdominal MRI revealed a tumor in S4-1 and S8 of the liver. We diagnosed the tumor as an unresectable hepatocellular carcinoma. After atezolizumab and bevacizumab combination therapy, we evaluated the partial response(PR)using the response evaluation criteria in solid tumors(RECIST)and performed laparoscopic cholecystectomy and left lobectomy. There are no established indications for conversion surgery for unresectable hepatocellular carcinoma after combination therapy with atezolizumab and bevacizumab, and more cases should be studied to determine the indications and optimal timing of conversion surgery.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 2","pages":"176-178"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}